None
NL
Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $8.50
['Defense World Staff']
Defense World
View Our Latest Analysis on C4 TherapeuticsC4 Therapeutics Stock Down 3.2%C4 Therapeutics stock opened at $2.15 on Monday.
C4 Therapeutics has a 12 month low of $1.09 and a 12 month high of $7.14.
C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%.
On average, equities research analysts expect that C4 Therapeutics will post -1.52 earnings per share for the current fiscal year.
Further ReadingReceive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.